Priority Lists
Protocol Posting of
Activations
Closures
Amendments, Revisions, Memoranda
Amendment #2
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paciltaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients with Axillary Node-Positive or High-Risk Node Negative Breast Cancer
| Study Coordinator(s) | Silvana Martino, D.O. |
| Participants | Members, Medical Oncologists, Pathologists, NCORP, Surgeons |
Revision #4
Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma
| Study Coordinator(s) | Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY |
Revision #5
A Randomized Comparison of Medroxyprogesterone Acetate (MPA) and Observation For Prevention of Endometrial Pathology in Postmenopausal Breast Cancer Patients Treated with Tamoxifen
| Study Coordinator(s) | Ronald K. Potkul, M.D., Caryl G. Salomon, M.D., Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, CALGB, NCORP |
Revision #6
Enhancing Well-Being During Breast Cancer Recurrence
| Study Coordinator(s) | Carolyn C. Gotay, Ph.D., Carol M. Moinpour, Ph.D., Silvana Martino, D.O., Bonnie M. Taylor, Ph.D. |
| Participants | Medical Oncologists, NCORP, Members |
Revision #6
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer, Phase III.
| Study Coordinator(s) | Daniel P. Petrylak, M.D., Jeffrey A. Jones, M.D., Maha H.A. Hussain, M.D., Donna L. Berry, R.N.,Ph.D. |
| Participants | UCOP, Medical Oncologists, Surgeons, CALGB, NCCTG, EPP, NCORP, Members, CTSU |
Amendment #2
Chemoprevention Trial to Prevent Second Primary Tumors with Low-Dose 13-Cis Retinoic Acid in Head and Neck Cancer
| Study Coordinator(s) | Harinder S. Garewal, M.D.,Ph.D. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required